BioCryst to Sell European ORLADEYO® Business for up to $264 Million
Why we think this is good
The RNS announcement regarding BioCryst's sale of its European ORLADEYO® business for up to $264 million is positive news for the company. The transaction will allow BioCryst to retire all of its remaining term debt, including $99.5 million owed to BioPharma Credit PLC, which should improve the company's financial position. Additionally, the Company will receive a 3% prepayment premium on the principal repaid, which is a favorable contractual term. While this is a significant transaction for BioCryst, it does not meet the criteria for a 'Very Good' rating as it is not a profit upgrade or trading significantly ahead of expectations. Therefore, the sentiment score is capped at 'Good'.
Key Points
- BioCryst to sell European ORLADEYO® business to Neopharmed Gentili for up to $264 million
- Proceeds will be used to retire all remaining term debt of $248.7 million, including $99.5 million owed to BioPharma Credit PLC
- Company will receive a 3% prepayment premium on the principal repaid
Summary
BioCryst Pharmaceuticals, Inc. has entered into a definitive agreement to sell its European ORLADEYO® (berotralsat) business to Neopharmed Gentili for up to $264 million. BioCryst expects to close the sale by early October 2025 and plans to use the proceeds to retire all remaining term debt of $248.7 million, including $99.5 million owed to BioPharma Credit PLC. The Company will also receive a 3% prepayment premium on the principal repaid.